Summit Therapeutics Inc. Summit Therapeutics Inc.

Summit Therapeutics Inc.

SMMT

Rang in Aktien #1663
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aktienkurs
$16.14
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$12.87B
Veränderung (1 Tag)
3.65%
Veränderung (1 Jahr)
-13.88%
Land
US
Handel Summit Therapeutics Inc. (SMMT)

Kategorie

Healthcare
Aktien-Split-Historie für Summit Therapeutics Inc. (SMMT)
Die Aktie Summit Therapeutics Inc. (Symbol: SMMT) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Oct 21, 2026 statt.
Eine SMMT-Aktie, die vor dem Oct 21, 2026 gekauft wurde, entspricht heute 0 SMMT-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL